Nov 19, 2019: Karuna Therapeutics announced  that KarXT assured for the treatment of acute psychosis in schizophrenia patient sign up in a Phase II clinical trial.
KarXT (xanomeline and trospium) stimulates muscarinic receptors in the central nervous system (CNS) and used for the treatment of psychosis and related symptoms. Xanomeline (muscarinic receptor agonist), while trospium (muscarinic receptor antagonist)are  expected to avoid the side effects that are seen with existing antipsychotic standard of care drugs.
Discontinuation and tolerated  rates of KarXT were found to be similar between the treatment and placebo arms.The adverse event (AE) rate with KarXT and placebo was found to be 54% and 43%, respectively. https://www.clinicaltrialsarena.com/news/karuna-therapeutics-schizophrenia-data/
